Analyst picks & changes

Cephalon Inc.

(CEPH)

Chiron Corp.

(CHIR)

Analysts were virtually — but not quite — unanimous in their rave reviews of data from CEPH's Phase II/III trial of Myotrophin

IGF-1

in amyotrophic lateral sclerosis (see BioCentury Extras June 12 and 13).

Peter Ginsberg of Vector Securities International expects Myotrophin to rapidly penetrate the $250 million U.S. ALS market because there's no approved treatment, the disease is almost uniformly

Read the full 688 word article

How to gain access

Continue reading with a
two-week free trial.